Developing countries vaccine manufacturers network: Doing good by making high-quality vaccines affordable for all

Vaccine

Volumn 31, Issue SUPPL2, 2013, Pages

  Pagliusi, Sonia ^a   Leite, Luciana C C ^b   Datla, Mahima ^c   Makhoana, Morena ^d   Gao, Yongzhong ^e   Suhardono, Mahendra ^f   Jadhav, Suresh ^g   Harshavardhan, Gutla V J A ^h   Homma, Akira ⁱ  

^a DCVMN International   (Switzerland)

^b INSTITUTO BUTANTAN   (Brazil)

^c Biological E Ltd   (India)

^d Biovac Institute   (South Africa)

^e Xiamen Innovax Biotech   (China)

^f PT Biofarma   (Indonesia)

^g Serum Institute of India Ltd   (India)

^h Bharat Biotech International Ltd   (India)

ⁱ Instituto de Technologia em Imunobiologicos   (Brazil)

Author keywords

Procurement; Quality control; Technology transfer; Vaccine manufacture

Indexed keywords

ANTHRAX VACCINE; BCG VACCINE; CHICKENPOX VACCINE; CHOLERA VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HEPATITIS E VACCINE; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; LEPTOSPIROSIS VACCINE; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; RABIES VACCINE; ROTAVIRUS VACCINE; RUBELLA VACCINE; TETANUS TOXOID; TYPHOID VACCINE; VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

ANTHRAX; CHICKENPOX; CHOLERA; DIPHTHERIA; DRUG MANUFACTURE; HAEMOPHILUS INFECTION; HEMORRHAGIC FEVER; HEPATITIS A; HEPATITIS B; HEPATITIS E; HUMAN; INFLUENZA; JAPANESE ENCEPHALITIS; LEPTOSPIROSIS; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; RABIES; REVIEW; ROTAVIRUS INFECTION; RUBELLA; TETANUS; TUBERCULOSIS; TYPHOID FEVER; VERRUCA VULGARIS; YELLOW FEVER;

DEVELOPING COUNTRIES; DRUG INDUSTRY; HUMANS; INTERNATIONAL COOPERATION; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; TECHNOLOGY TRANSFER; VACCINES;

EID: 84876732785     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.060     Document Type: Review

References (28)

1. Poeloengan T., Raw I., Martinez L.H., El-Abbadi M. Developing Country Vaccine Manufacturers Network (DCVMN), 26-27 April 2001, Bandung, Indonesia. Vaccine 2001, 20:285-287.
2. Jadhav S., Datla M., Kreeftenberg H., Hendriks J. The developing countries vaccine manufacturers' network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries. Vaccine 2008, 26:1611-1615.
3. Measles, Key facts, Fact sheet No. 286, April 2012. Available at . http://www.who.int/mediacentre/factsheets/fs286/en/index.html.
4. Ali S.S., Chandrashekar S.R., Singh M., Bansal R.K., Sharma D.R., Arora D. A multicenter, prospective, open-label, non-comparative study to evaluate the immunogenicity and tolerance of a new, fully liquid pentavalent vaccine (DTwP-HepB-Hib vaccine). Hum Vaccin 2007, 3:116-120.
5. Information available at , consulted on July 15th, 2012. http://www.unicef.org/supply/files/12_01_13_DTP-HepB-Hib.pdf.
6. Connecting for a cause. DCVMN brochure. Available at . http://www.dcvmn.org/.
7. Global Allert and Response: meningococcal diseases: . http://www.who.int/csr/don/archive/disease/meningococcal_disease/en/index.html.
8. WHO report: Viral Hepatitis in the WHO South East Asia Region. http://www.searo.who.int/LinkFiles/Diarrhoea,_ARI_and_hepatitis_SEA-CD-232.pdf.
9. Zhu F.C., Zhang J., Zhang X.F., Zhou C., Wang Z.Z., Huang S.J., et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010, 376:895-902.
10. World Health Organization, Water-related diseases, Japanese Encephalitis. http://www.who.int/water_sanitation_health/diseases/encephalitis/en/.
11. http://www.nhs.uk/Conditions/Japanese-encephalitis/Pages/Beforeyougo.aspx.
12. Zorzeto T.Q., Higashi H.G., da Silva M.T., Carniel Ede F., Dias W.O., Ramalho V.D., et al. Immunogenicity of a whole-cell pertussis vaccine with low lipopolysaccharide content in infants. Clin Vaccine Immunol 2009, 16:544-550.
13. Quintilio W., Kubrusly F.S., Iourtov D., Miyaki C., Sakauchi M.A., Lúcio F., et al. Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice. Vaccine 2009, 27:4219-4224.
14. Precioso A.R., Miraglia J.L., Campos L.M., Goulart A.C., Timenetsky Mdo C., Cardoso M.R., et al. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems. Vaccine 2011, 8:8974-8981.
15. India records one year without polio cases. WHO Media Centre, News Release, 12 January 2012. http://www.who.int/mediacentre/news/releases/2012/polio_20120113/en/.
16. Aylward R.B. Eradicating polio: today's challenges and tomorrow's legacy" . Ann Trop Med Parasitol 2006, 100:401-413.
17. WHO facilitates new polio vaccine technology transfer , call for expressions of interest (EoI). Developing Sabin-inactivated polio vaccine (sIPV) 2012. Available at: . http://www.polioeradication.org/Portals/0/Document/Research/EOI_POL_20120427.pdf.
18. Bakker W.A., Thomassen Y.E., van't Oever A.G., Westdijk J., van Oijen M.G., Sundermann L.C., et al. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine 2011, 29:7188-7196.
19. Resik S., Tejeda A., Lago P.M., Diaz M., Carmenates A., Sarmiento L., et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis 2010, 201:1344-1352.
20. Perdue M.L., Nguyen T. The WHO research agenda for influenza: two years later. Bull World Health Organ 2012, 90:246. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324863/pdf/BLT.11.090175.pdf.
21. Osterhaus A., Fouchier R., Rimmelzwaan G. Towards universal influenza vaccines. Philos Trans R Soc Lond B Biol Sci 2011, 366:2766-2773.
22. Perdue M.L., Arnold F., Li S., Donabedian A., Cioce V., Warf T., et al. The future of cell culture-based influenza vaccine production. Expert Rev Vaccines 2011, 10:1183-1194.
23. Hendriks J., Holleman M., de Boer O., de Jong P., Luytjes W. An international technology platform for influenza vaccines. Vaccine 2011, 29(Suppl 1):A8-A11.
24. Miyaki C., Meros M., Precioso A.R., Raw I. Influenza vaccine production for Brazil: a classic example of successful North-South bilateral technology transfer. Vaccine 2011, 29(Suppl. 1):A12-A15.
25. Milstien J., Costa A., Jadhav S., Rajeev Dhere Reaching international GMP standards for vaccine production: challenges for developing countries. Expert Rev Vaccines 2009, 8:559-566. [review].
26. Cortes Mde L., Cardoso D., Fitzgerald J., DiFabio J.L. Public vaccine manufacturing capacity in the Latin American and Caribbean region: current status and perspectives. Biologicals 2012, 40:3-14.
27. UNICEF procurement and supply overview; 2011. http://www.unicef.org/supply/files/UNICEF_Supply_Annual_Report_2011_web.pdf.
28. Jadhav S.S., Gautam M., Gairola S. Emerging markets & emerging needs: developing countries vaccine manufacturers' perspective & its current status. Biologicals 2009, 37:165-168.